Novo Nordisk, Facet Biosystems advances partnership for diabetes therapies
Novo Nordisk and Facet Biosystems have entered a brand new section of their ongoing collaboration centered on healing mobile medicines for the therapy of diabetes.
The collaboration, which started in 2023, goals to create therapies that may exchange, restore or complement organic capabilities in sufferers, advancing the event of disease-modifying therapies.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
Below the settlement, Facet acquired rights from Novo Nordisk to stem cell-derived islet cell and hypo-immune cell know-how.
Facet will assume duty for the event, manufacturing and commercialization of those therapies.
Novo Nordisk retains sure rights to increase its function in later improvement and commercialization.
Novo Nordisk will enhance its fairness funding in Facet and supply analysis funding to advance the therapies. In return, Novo Nordisk will obtain royalties and milestone funds from Facet tied to future product gross sales.
The settlement specifies that sure cell remedy analysis, improvement and manufacturing capabilities from Novo Nordisk websites within the US and Denmark might be built-in into Facet’s Canadian-based platform.
This step is meant to enhance Facet’s end-to-end capabilities.
Facet makes use of its platform to develop allogeneic mobile therapeutics for metabolic and endocrine illnesses.
Novo Nordisk World Analysis senior vice chairman Jacob Sten Petersen mentioned: “Novo Nordisk was based on a dedication to enhancing the lives of individuals with diabetes. That dedication is as robust right this moment because it was 100 years in the past, and we now have a continued deal with bringing innovation to folks residing with sort 1 diabetes by inner and exterior innovation efforts.
“Facet brings large experience and capabilities within the subject of mobile medication, and we’re proud to collaborate with them to advance transformative cell therapies towards medical improvement and probably generate a practical treatment for folks with diabetes.”
In September 2025, Novo Nordisk acquired approval from the Committee for Medicinal Merchandise for Human Use (CHMP) of the European Medicines Company (EMA) for the replace of the Rybelsus (oral semaglutide) label.
